

Blue Cross and Blue Shield of Illinois Provider Manual

HMO Scope of Benefits Section

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

Synagis[®]

Benefit

This immunization is in benefit for infants at high risk for developing Respiratory Syncytial Virus (RSV) infection.

Interpretation

Synagis® is administered to prevent lower respiratory infections caused by RSV in pediatric members at high risk of death or disability from RSV infection. Such members may have a history of prematurity or bronchopulmonary dysplasia. Members should receive monthly doses starting before the commencement of the RSV season, which is typically November through April.

This immunization is given intramuscularly and is not classified as self-injectable. As with all immunizations and other non-self-injectable medications, Synagis® is the financial responsibility of the IPA.

Note: See related benefit Guideline on Drugs, Immunizations